Skip to content

Effect of Adipose Derived Stem Cells on Survival of Fat as Filler

Effect of Adipose Derived Stem Cells on Survival of Fat as Filler

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03965936
Enrollment
15
Registered
2019-05-29
Start date
2019-01-01
Completion date
2019-07-16
Last updated
2019-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Rejuvenation, Lipofilling

Keywords

adipose tissue derived stem cells, lipofilling

Brief summary

this research is to study the effect of Adipose Derived Stem Cells on Survival of Fat as Filler

Detailed description

Skin aging is a complex biological process.The physiological changes associated with aging of the skin are manifested in xerosis, dramatic loss of skin elasticity due to damage to collagen and elastin fibers; as well as barrier function, modification of rhytides and deficiencies in the regenerative property of the skin. All of which ultimately result in thinning of the skin, malar fat atrophy and pigmentary changes. Autologous fat grafting or lipo injection containing stromal vascular fraction (SVF) acts like ideal soft tissue filler for facial filling and rejuvenation. It leads to progressive improvement of the skin texture, elasticity, and color over a few months, therefore adipose tissue seems to be not only a simple filler but also a dynamic filler with two types of different and supplementary effects, the volumetric effect and the regenerative effect.Cell assisted lipotransfer (CAL) is a technique that combines aspirated fat with concentrated ADSCs in the stromal vascular fraction (SVF) of the lipoaspirate. This technique could enhance the survival rate of the transplanted fat and leads to better cosmetic improvement

Interventions

PROCEDURElipofilling

Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.

PROCEDURElipofilling enriched with adipose tissue derived stem cells

Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine. Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region.

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

split face

Eligibility

Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Clinically diagnosed facial skin aging. 2. Glogau photoaging score II and III. 3. Body mass index ≥20 with adequate abdominal or other subcutaneous adipose tissue accessible for lipoaspiration.

Exclusion criteria

1. History of keloid formation. 2. Any coincidental chronic illness (e.g. metabolic, autoimmune or endocrinal) or malignancy. 3. Any bleeding or coagulation disorder or recent use of anticoagulant therapy. 4. Active infection. 5. History of any previous aesthetic procedure on the face within the past 6 months. 6. History of intake of anti-aging systemic or topical medications within the previous 3 months

Design outcomes

Primary

MeasureTime frameDescription
Assessment using hollowness severity rating scale :0 : no visible hollowness, 1: mild Hollowness, 2 : moderate Hollowness, 3: severe Hollowness3 months, 6 monthsserial photography for assessment using hollowness severity rating scale :0 : no visible hollowness, 1: mild Hollowness, 2 : moderate Hollowness, 3: severe Hollowness

Secondary

MeasureTime frameDescription
Measurement of hypodermal thickness in mm using UBM (Ultrasound Bio microscopy) on both temple regions of the head3 months, 6 monthsMeasurement of hypodermal thickness in mm using UBM (Ultrasound Bio microscopy) on both temple regions of the head
Measurement of dermal thickness in mm using UBM (Ultrasound Bio microscopy) on both temple regions of the head Measurement of dermal thickness in mm using UBM (Ultrasound Bio microscopy) on both temple regions of the head3 months, 6 monthsMeasurement of dermal thickness in mm using UBM (Ultrasound Bio microscopy) on both temple regions of the head

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026